185 related articles for article (PubMed ID: 12858437)
1. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study.
Nishimoto N; Yoshizaki K; Maeda K; Kuritani T; Deguchi H; Sato B; Imai N; Suemura M; Kakehi T; Takagi N; Kishimoto T
J Rheumatol; 2003 Jul; 30(7):1426-35. PubMed ID: 12858437
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS
Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
[TBL] [Abstract][Full Text] [Related]
3. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.
Nishimoto N; Yoshizaki K; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Hashimoto J; Azuma J; Kishimoto T
Arthritis Rheum; 2004 Jun; 50(6):1761-9. PubMed ID: 15188351
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis.
Yokota S; Miyamae T; Imagawa T; Iwata N; Katakura S; Mori M; Woo P; Nishimoto N; Yoshizaki K; Kishimoto T
Arthritis Rheum; 2005 Mar; 52(3):818-25. PubMed ID: 15751095
[TBL] [Abstract][Full Text] [Related]
5. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.
Westhovens R; Houssiau F; Joly J; Everitt DE; Zhu Y; Sisco D; Van Hartingsveldt B; Mascelli MA; Graham MA; Durez P; Bouman-Thio E
J Rheumatol; 2006 May; 33(5):847-53. PubMed ID: 16583466
[TBL] [Abstract][Full Text] [Related]
6. Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study.
Straub RH; Härle P; Yamana S; Matsuda T; Takasugi K; Kishimoto T; Nishimoto N
Arthritis Rheum; 2006 Jun; 54(6):1778-85. PubMed ID: 16729287
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.
Haringman JJ; Gerlag DM; Smeets TJ; Baeten D; van den Bosch F; Bresnihan B; Breedveld FC; Dinant HJ; Legay F; Gram H; Loetscher P; Schmouder R; Woodworth T; Tak PP
Arthritis Rheum; 2006 Aug; 54(8):2387-92. PubMed ID: 16869001
[TBL] [Abstract][Full Text] [Related]
8. [A humanized anti-IL-6 receptor antibody(MRA) in RA therapy].
Hagihara K; Nishimoto N; Yoshizaki K
Nihon Rinsho; 2002 Dec; 60(12):2401-7. PubMed ID: 12510369
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis.
Furst DE; Fleischmann R; Kopp E; Schiff M; Edwards C; Solinger A; Macri M;
J Rheumatol; 2005 Dec; 32(12):2303-10. PubMed ID: 16331754
[TBL] [Abstract][Full Text] [Related]
10. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
Scott AM; Wiseman G; Welt S; Adjei A; Lee FT; Hopkins W; Divgi CR; Hanson LH; Mitchell P; Gansen DN; Larson SM; Ingle JN; Hoffman EW; Tanswell P; Ritter G; Cohen LS; Bette P; Arvay L; Amelsberg A; Vlock D; Rettig WJ; Old LJ
Clin Cancer Res; 2003 May; 9(5):1639-47. PubMed ID: 12738716
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.
Davis JC; Totoritis MC; Rosenberg J; Sklenar TA; Wofsy D
J Rheumatol; 2001 Jan; 28(1):95-101. PubMed ID: 11196549
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.
Lü LJ; Teng JL; Bao CD; Han XH; Sun LY; Xu JH; Li XF; Wu HX
Chin Med J (Engl); 2008 Apr; 121(7):615-9. PubMed ID: 18466681
[TBL] [Abstract][Full Text] [Related]
13. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study.
Burge DJ; Bookbinder SA; Kivitz AJ; Fleischmann RM; Shu C; Bannink J
Clin Ther; 2008 Oct; 30(10):1806-16. PubMed ID: 19014836
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept.
Haraoui B; Keystone EC; Thorne JC; Pope JE; Chen I; Asare CG; Leff JA
J Rheumatol; 2004 Dec; 31(12):2356-9. PubMed ID: 15570634
[TBL] [Abstract][Full Text] [Related]
16. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis.
Abe T; Takeuchi T; Miyasaka N; Hashimoto H; Kondo H; Ichikawa Y; Nagaya I
J Rheumatol; 2006 Jan; 33(1):37-44. PubMed ID: 16395748
[TBL] [Abstract][Full Text] [Related]
18. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis.
Moreland LW; Margolies G; Heck LW; Saway A; Blosch C; Hanna R; Koopman WJ
J Rheumatol; 1996 Nov; 23(11):1849-55. PubMed ID: 8923355
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R
J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
Keystone E; Fleischmann R; Emery P; Furst DE; van Vollenhoven R; Bathon J; Dougados M; Baldassare A; Ferraccioli G; Chubick A; Udell J; Cravets MW; Agarwal S; Cooper S; Magrini F
Arthritis Rheum; 2007 Dec; 56(12):3896-908. PubMed ID: 18050221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
